Carbamazepine Extended-Release Capsules (Equetro) and Invega Sustenna injection
Determining the interaction of Carbamazepine Extended-Release Capsules (Equetro) and Invega Sustenna injection and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using carBAMazepine together with paliperidone may decrease the effects of paliperidone. Contact your doctor if your condition changes. You should be monitored for signs of reduced efficacy for 2 to 3 weeks after carBAMazepine is added, discontinued, or its dose is changed. You may need a dose adjustment or special test if you use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: The concomitant use of potent inducers of P-glycoprotein (P-gp) efflux transporters such as carbamazepine may reduce plasma concentrations of paliperidone and its efficacy. The proposed mechanism is induction of renal P-gp. Average maximum plasma concentrations (Cmax) and AUC of paliperidone decreased by 37% and the renal clearance increased by 35% during concurrent administration of carbamazepine 200 mg twice a day. Larger doses may result in larger reductions in paliperidone plasma levels. P-gp induction may take 2 to 3 weeks to reach steady state after a P-gp-inducing drug is initiated, and as long to wear off after the inducer is discontinued. Other P-gp inducers such as rifampin and St. John's wort may also interact, although clinical data have not been reported.
MANAGEMENT: Patients should be monitored for signs of reduced efficacy during concomitant use and for 2 to 3 weeks after a P-gp-inducing drug is added, discontinued, or its dose is changed. Dose adjustments of paliperidone may be required.
- Cerner Multum, Inc. "Australian Product Information." O 0
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Generic Name: carbamazepine
Brand name: Carbatrol, Epitol, Equetro, Tegretol, Tegretol XR, Tegretol, Tegretol XR
Synonyms: Carbamazepine, CarBAMazepine
Generic Name: paliperidone
Brand name: Invega Sustenna, Invega Trinza, Invega
Synonyms: Invega Sustenna (injection), Invega Sustenna
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Carbamazepine Extended-Release Capsules (Equetro)-Invega Trinza
- Carbamazepine Extended-Release Capsules (Equetro)-Invega Trinza injection
- Carbamazepine Extended-Release Capsules (Equetro)-Inveltys
- Carbamazepine Extended-Release Capsules (Equetro)-Inveltys ophthalmic
- Carbamazepine Extended-Release Capsules (Equetro)-Inversine
- Carbamazepine Extended-Release Capsules (Equetro)-Invirase
- Invega Sustenna injection-Carbamazepine Extended-Release Tablets
- Invega Sustenna injection-Carbamazepine Intravenous
- Invega Sustenna injection-Carbamazepine Oral Suspension
- Invega Sustenna injection-Carbamazepine Tablets
- Invega Sustenna injection-Carbaphen 12
- Invega Sustenna injection-Carbaphen CH